Advisory Board at a Resort with Off-Label Discussion
A pharmaceutical company is planning a two-day advisory board at a luxury resort for 10 community oncologists. The drug is approved only for second-line metastatic breast cancer, but the agenda includes a session titled 'Exploring first-line and adjuvant opportunities.' Each advisor will receive a $5,000 honorarium, and spouses are invited to dinners and a spa afternoon. The sales team will host a dinner on night one and wants to use the advisors' comments to draft promotional talking points. The draft minutes have not been prepared, and no needs assessment or written agreements exist. The VP of marketing says the meeting is 'scientific' because the advisors are experts. The compliance officer must decide whether to approve the meeting, what to change, and what to report. The meeting is in three weeks.
1. Identify the main compliance concerns in this advisory board plan.
Read the worked answer
The meeting has several red flags. A $5,000 honorarium may be above fair market value for two days of advisory work unless there is a documented rationale, and the lack of written agreements and minutes makes it look like payment for access. Spouses and spa treatments are entertainment, not consulting, and should not be paid. The session on first-line and adjuvant use is off-label relative to the approved second-line indication. Off-label scientific exchange can be legitimate, but the company cannot use an advisory board as a pretext to develop or test off-label promotional messages. Sales hosting dinner and drafting promotional talking points from advisor comments blurs consulting and promotion. The luxury resort increases the appearance problem.
2. What changes and documentation would you require before approving the meeting?
Read the worked answer
I would not approve as designed. Required changes: a written needs assessment and agenda focused on legitimate scientific questions; written consulting agreements with deliverables, term, and fair-market-value rate; a documented FMV analysis for the $5,000 honorarium; no spouses, spa, or other entertainment; modest meals; no sales team participation in the advisory sessions, and no use of advisor comments for promotional talking points; minutes that record the scientific advice, not marketing messages; and a clear separation between the advisory board and any promotional activity. If the company wants off-label discussion, it should be framed as scientific exchange and reviewed by medical and regulatory, not marketing.
3. What reporting and recordkeeping obligations apply, and what should the compliance officer do if the changes are refused?
Read the worked answer
The company must report the honoraria and any travel and meals as transfers of value to physician advisors under applicable transparency rules. It should also keep records of the selection criteria, the services performed, and the fair-market-value support. The advisors should disclose their relationships as required. If the company cannot justify the honorarium or refuses to remove spouses, spa, and sales involvement, the compliance officer should decline the meeting. The safest path is to convert it into a properly documented advisory board with medical affairs leadership, or cancel it.